Nika Pharmaceuticals, Inc (NIKA) stock
NIKAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.41+0.00 (0.00%)
Close on Oct 16, 2026Market cap $431.19MP/E –Yield –
Nika Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nika Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$78.14K. For fiscal 2025 it was -$76.40K. The highest annual figure on record is -$8.91K in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.40K | – |
| FY2024 | Dec 31, 2024 | -$95.79K | – |
| FY2023 | Dec 31, 2023 | -$64.83K | – |
| FY2022 | Dec 31, 2022 | -$3.18M | – |
| FY2021 | Dec 31, 2021 | -$14.71K | – |
| FY2020 | Dec 31, 2020 | -$8.91K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.69K | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.36K | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.09K | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.38K | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.95K | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.45K | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.95K | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.31K | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.14K | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.14K | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.57K | -409.8% |
| Q4 FY2022 | Dec 31, 2022 | -$15.05K | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.34K | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.16M | – |
| Q1 FY2022 | Mar 31, 2022 | $6.32K | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.30K | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.70K | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.96K | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.75K | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.75K | – |
| Q3 FY2020 | Sep 30, 2020 | -$160 | – |
See a number that looks wrong?